Enhertu demonstrates durable response in patients across HER2 expressing advanced solid tumors

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Clinical Roundup

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Immunological features predict treatment response for advanced solid tumors

The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.

September 13, 2024

Vol.50 No.34

In Brief

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

Jennifer Munson has been named director of the Fralin Biomedical Research Institute at VTC’s Cancer Research Center in Roanoke, VA.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Cancer cells salvage purine nucleotides—including dietary purines—to fuel tumor growth

Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children’s Medical Center Research Institute at UT Southwestern published in Cell.

July 19, 2024

Vol.50 No.29

Drugs & Targets

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.

June 14, 2024

Vol.50 No.24

Enhertu demonstrates durable response in patients across HER2 expressing advanced solid tumors

YOU MAY BE INTERESTED IN

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

Immunological features predict treatment response for advanced solid tumors

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

Cancer cells salvage purine nucleotides—including dietary purines—to fuel tumor growth

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

Renew today!

Subscriber content

Login